Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 3/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30061412 | 1.00 | GPR119 (0.38) | GPR119HSD11B1JAK1JAK2TYK2 | |
| SCHEMBL21684836 | 0.86 | — | — | |
| SCHEMBL20722670 | 0.80 | HSD11B1 (0.38) | GPR119HSD11B1JAK1JAK2TYK2 | |
| SCHEMBL30062061 | 0.80 | HSD11B1 (0.38) | GPR119HSD11B1JAK1JAK2TYK2 | |
| SCHEMBL31105124 | 0.77 | HSD11B1 (0.44) | GPR119HSD11B1JAK1JAK2TYK2 | |
| SCHEMBL30427174 | 0.77 | HSD11B1 (0.44) | GPR119HSD11B1JAK1JAK2TYK2 | |
| SCHEMBL20722688 | 0.74 | JAK1 (0.39) | GPR119HSD11B1JAK1JAK2TYK2 | |
| SCHEMBL30060077 | 0.74 | JAK1 (0.39) | GPR119HSD11B1JAK1JAK2TYK2 | |
| SCHEMBL20722417 | 0.74 | JAK1 (0.39) | GPR119HSD11B1JAK1JAK2TYK2 | |
| SCHEMBL30968429 | 0.72 | GPR119 (0.31) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162888-B2 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-20210323975-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | VALO EARLY DISCOVERY, INC. | 2021-10-21 | — | — | US | disclosed |
| EP-3833661-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | Valo Early Discovery, Inc. (US) | 2021-06-16 | — | — | EP | disclosed |
| CN-112867712-A | Carboxamides as ubiquitin-specific protease inhibitors | 瓦洛早期发现股份有限公司 | 2021-05-28 | — | — | CN | disclosed |
| EP-3665169-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | Forma Therapeutics, Inc. (US) | 2020-06-17 | — | — | EP | disclosed |
| WO-2020033707-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2020-02-13 | — | — | WO | disclosed |
| WO-2019032863-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2019-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | GPR119 4020/4885HSD11B1 4134/4885JAK1 1927/4885 |
| US-20210323975-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | USP28, USP25, USP24 | GPR119 4020/4885HSD11B1 4134/4885JAK1 1927/4885 |
| US-12162888-B2 | Carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | GPR119 4020/4885HSD11B1 4134/4885JAK1 1927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.